Adeno-associated viral vectors at the frontier between tolerance and immunity

Frontiers in Immunology

Volumn 6, Issue MAR, 2015, Pages

  Mingozzi, Federico ^a,b   Büning, Hildegard ^c,d,e  

^a GÉNÉTHON   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c UNIVERSITY OF COLOGNE   (Germany)

^d UNIVERSITY OF BONN   (Germany)

^e UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

AAV vector; Gene therapy; Immune response; Tolerance; Vaccine

Indexed keywords

ADENOVIRUS VECTOR;

EDITORIAL; GENE EXPRESSION; HUMAN; IMMUNE SYSTEM; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE;

EID: 84926641637     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2015.00120     Document Type: Editorial

References (25)

1. Mingozzi F, High KA. Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat Rev Genet (2011) 12:341-55. doi: 10.1038/nrg2988.
2. Buning H. Gene therapy enters the pharma market: the short story of a long journey. EMBO Mol Med (2013) 5:1-3. doi:10.1002/emmm.201202291.
3. Gormley B. Therapies Push Investors to Examine New Areas of Human Body. Wall Street Journal Venture Capital Dispatch (2014). Available from: http://blogs.wsj.com/venturecapital/2014/09/14/gene-therapies-push-investors-to-examine-new-areas-of-human-body/.
4. Muzyczka N, Berns KI. Parvoviridae: The Viruses and their Replication. Edn. 4th ed. Philadelphia, PA: Lippincott, Williams and Wilkins (2001).
5. Buchlis G, Podsakoff GM, Radu A, Hawk SM, Flake AW, Mingozzi F, et al. Factor IX expression in skeletal muscle of a severe hemophilia B patient 10 years after AAV-mediated gene transfer. Blood (2012) 119:3038-41. doi:10.1182/blood-2011-09-382317.
6. Nathwani AC, Reiss UM, Tuddenham EG, Rosales C, Chowdary P, McIntosh J, et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med (2014) 371:1994-2004. doi:10.1056/NEJMoa1407309.
7. Bartel M, Schaffer D, Buning H. Enhancing the clinical potential of AAV vectors by capsid engineering to evade pre-existing immunity. Front Microbiol (2011) 2:204. doi:10.3389/fmicb.2011.00204.
8. McCarty DM, Fu H, Monahan PE, Toulson CE, Naik P, Samulski RJ. Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo. Gene Ther (2003) 10:2112-8. doi:10.1038/sj.gt.3302134.
9. Mingozzi F, Liu YL, Dobrzynski E, Kaufhold A, Liu JH, Wang Y, et al. Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer. J Clin Invest (2003) 111:1347-56. doi:10.1172/JCI200316887.
10. Nieto K, Salvetti AAAV. Vectors vaccines against infectious diseases. Front Immunol (2014) 5:5. doi:10.3389/fimmu.2014.00005.
11. Liao G, O'Keeffe MS, Wang G, van Driel B, de Waal Malefyt R, Reinecker HC, et al. Glucocorticoid-induced TNF receptor family-related protein ligand is requisite for optimal functioning of regulatory CD4(+) T cells. Front Immunol (2014) 5:35. doi:10.3389/fimmu.2014.00035.
12. Cao O, Furlan-Freguia C, Arruda VR, Herzog RW. Emerging role of regulatory T cells in gene transfer. Curr Gene Ther (2007) 7:381-90. doi:10.2174/156652307782151506.
13. Liu CL, Ye P, Lin J, Butts CL, Miao CH. Anti-CD20 as the B-Cell targeting agent in a combined therapy to modulate anti-factor VIII immune responses in hemophilia a inhibitor mice. Front Immunol (2014) 4:502. doi:10.3389/fimmu.2013.00502.
14. Hösel M, Broxtermann M, Janicki H, Esser K, Arzberger S, Hartmann P, et al. Toll-like receptor 2-mediated innate immune response in human nonparenchymal liver cells toward adeno-associated viral vectors. Hepatology (2012) 55:287-97. doi:10.1002/hep.24625.
15. Zhu J, Huang X, Yang Y. The TLR9-MyD88 pathway is critical for adaptive immune responses to adeno-associated virus gene therapy vectors in mice. J Clin Invest (2009) 119:2388-98. doi:10.1172/JCI37607.
16. Martino AT, Suzuki M, Markusic DM, Zolotukhin I, Ryals RC, Moghimi B, et al. The genome of self-complementary adeno-associated viral vectors increases Toll-like receptor 9-dependent innate immune responses in the liver. Blood (2011) 117:6459-68. doi:10.1182/blood-2010-10-314518.
17. Faust SM, Bell P, Cutler BJ, Ashley SN, Zhu Y, Rabinowitz JE, et al. CpG-depleted adeno-associated virus vectors evade immune detection. J Clin Invest (2013) 123:2994-3001. doi:10.1172/JCI68205.
18. Sudres M, Ciré S, Vasseur V, Brault L, Da Rocha S, Boisgérault F, et al. MyD88 signaling in B cells regulates the production of Th1-dependent antibodies to AAV. Mol Ther (2012) 20:1571-81. doi:10.1038/mt.2012.101.
19. Calcedo R, Wilson JM. Humoral immune response to AAV. Front Immunol (2013) 4:341. doi:10.3389/fimmu.2013.00341.
20. Tseng YS, Agbandje-McKenna M. Mapping the AAV capsid host antibody response toward the development of second generation gene delivery vectors. Front Immunol (2014) 5:9. doi:10.3389/fimmu.2014.00009.
21. Willett K, Bennett J. Immunology of AAV-mediated gene transfer in the eye. Front Immunol (2013) 4:261. doi:10.3389/fimmu.2013.00261.
22. Ferreira V, Petry H, Salmon F. Immune responses to AAV-vectors, the glybera example from bench to bedside. Front Immunol (2014) 5:82. doi:10.3389/fimmu.2014.00082.
23. Basner-Tschakarjan E, Mingozzi F. Cell-mediated immunity to AAV vectors, evolving concepts and potential solutions. Front Immunol (2014) 5:350. doi:10.3389/fimmu.2014.00350.
24. Basner-Tschakarjan E, Bijjiga E, Martino AT. Pre-clinical assessment of immune responses to adeno-associated virus (AAV) vectors. Front Immunol (2014) 5:28. doi:10.3389/fimmu.2014.00028.
25. Britten CM, Walter S, Janetzki S. Immunological monitoring to rationally guide AAV gene therapy. Front Immunol (2013) 4:273. doi:10.3389/fimmu.2013.00273.